Immuron CEO, Steven Lydeamore to present at AusBioInvest
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, announced its participation in AusBioInvest 2022 in Perth on October 27, 2022. CEO Steven Lydeamore will present a slide deck detailing the company’s oral immunotherapeutic products for gut-mediated diseases. Investors can access the presentation on the company’s website. This press release has been authorized by the directors of Immuron Limited.
- None.
- None.
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore.
A copy of the presentation slide deck is available on the Company’s website.
https://www.immuron.com.au/corporate-presentations/
This release has been authorised by the directors of Immuron Limited.
| COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information visit: http://www.immuron.com
FAQ
What is the date of Immuron Limited's presentation at AusBioInvest 2022?
Who is presenting for Immuron Limited at AusBioInvest 2022?
Where can investors find the presentation slide deck from Immuron Limited?
What does Immuron Limited specialize in?
What stock symbols are associated with Immuron Limited?
